Loading
Bladder and Urothelial Cancer Treatments / CRISPR and Genetic Engineering / Protease and Inhibitor Mechanisms · Journal article
Iubmb Life · September 1, 2026
Early or partial results. Treat as a signal, not a conclusion.
CRISPR-Cas9 knockout of MMP9 in murine bladder cancer cells reduced gene and protein expression, decreased integrin ITGB3, increased apoptotic BAX, and impaired migration and ECM adhesion in vitro. In an orthotopic mouse model, MMP9-knockout tumors showed improved survival and less weight loss than scramble controls; however, no synergistic benefit emerged when combined with BCG and anti-PD-L1 immunotherapy. This preclinical result suggests MMP9 is involved in bladder cancer malignancy but does not provide evidence that targeting it enhances established immunotherapies.
Preclinical orthotopic syngeneic tumor model in mice with CRISPR-Cas9 gene editing. Female C57BL/6 mice; MB49 murine bladder cancer cell line derived from C57BL/6 mice.. Intervention: CRISPR-Cas9 MMP9 knockout (MMP9-/-) with BCG and anti-PD-L1 immunotherapy.. Compared with: Scramble control cells with BCG and anti-PD-L1; scramble control alone.. Not stated..
MMP9 gene and protein expression were reduced in the MMP9-/- group compared with scramble control group Decreased ITGB3 and increased BAX gene expression observed in MMP9-/- group Reduced migration and adhesion to extracellular matrix in MMP9-/- cells
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This preclinical finding does not directly inform clinical practice. While MMP9 reduction shows biological activity in tumors, the failure to synergize with BCG and anti-PD-L1 suggests that MMP9-targeted therapy may not enhance standard immunotherapies; further research in human systems is required before clinical translation.
Early-phase in vivo mechanistic study in mice using CRISPR-Cas9 gene editing; demonstrates MMP9 knockout reduces bladder cancer malignancy but fails to achieve synergy with established immunotherapies, lacking human validation and clinical endpoints.
As stated by the source record.
Quoted from the source exactly as published.
This preclinical finding does not directly inform clinical practice. While MMP9 reduction shows biological activity in tumors, the failure to synergize with BCG and anti-PD-L1 suggests that MMP9-targeted therapy may not enhance standard immunotherapies; further research in human systems is required before clinical translation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Bladder cancer (BC) is the 10th most common cancer worldwide, accounting for approximately 5% of new cases. Several factors contribute to tumor progression, including increased MMP9. Recently, CRISPR-Cas9 and immunotherapy have offered high specificity for treatments; therefore, we edited MMP9 using CRISPR-Cas9 methodology to inhibit metastatic mechanisms and evaluated potential synergy with BCG and anti-PD-L1 therapy. We performed CRISPR-Cas9 gene editing using an RNP complex in the MB49 murine BC cell line. Gene expression of MMPs, integrins, and BAX was analyzed, along with protein expression. Cells were divided into a Scramble control group and CRISPR-Cas9 for the MMP9 edited group (MMP9-/-). Female C57BL/6 mice received orthotopic BC cells (scramble and MMP9-/- groups) treated with BCG and anti-PD-L1. Statistical analyses were performed using t test or ANOVA. MMP9 gene and protein expression were reduced in the MMP9-/- group compared with the scramble group. No differences were observed in other MMPs. Decreased ITGB3, increased BAX gene expression, as well as reduced migration and adhesion to ECM were observed in the MMP9-/- group. Animals in the scramble group showed greater weight loss and lower survival than treated groups. Overall, MMP9 modulated key cellular mechanisms, but did not show synergistic effects with BCG and anti-PD-L1 in vivo.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.